Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback